Amlexanox suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zhang, Yong ^a   Guan, Hanfeng ^a   Li, Jing ^a   Fang, Zhong ^a   Chen, Wenjian ^a   Li, Feng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPYRIDINE DERIVATIVE; AMLEXANOX; ANTIINFLAMMATORY AGENT; BONE DENSITY CONSERVATION AGENT; CYTOKINE;

ANIMAL; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; DOSE RESPONSE; DRUG EFFECTS; FEMALE; IMMUNOLOGY; MOUSE; OSTEOCLAST; OSTEOPOROSIS; OVARIECTOMY; PATHOLOGY; TREATMENT OUTCOME;

AMINOPYRIDINES; ANIMALS; ANTI-INFLAMMATORY AGENTS; BONE DENSITY CONSERVATION AGENTS; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MICE; MICE, INBRED C57BL; OSTEOCLASTS; OSTEOPOROSIS; OVARIECTOMY; TREATMENT OUTCOME;

EID: 84941051804     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13575     Document Type: Article

References (53)

1. Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337-342 (2003).
2. Arai, F. et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med. 190, 1741-1754 (1999).
3. Lacey, D. L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 (1998).
4. Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323 (1999).
5. Wada, T., Nakashima, T., Hiroshi, N. & Penninger, J. M. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 12, 17-25 (2006).
6. Leibbrandt, A. & Penninger, J. M. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 1143, 123-150 (2008).
7. Gohda, J. et al. RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J. 24, 790-799 (2005).
8. Negishi-Koga, T. & Takayanagi, H. Ca2+ -NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol Rev. 231, 241-256 (2009).
9. Takayanagi, H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 7, 292-304 (2007).
10. Teitelbaum, S. L. & Ross, F. P. Genetic regulation of osteoclast development and function. Nat Rev Genet. 4, 638-649 (2003).
11. Novack, D. V. & Teitelbaum, S. L. The osteoclast: friend or foe? Annu Rev Pathol. 3, 457-484 (2008).
12. Zhao, B., Grimes, S. N., Li, S., Hu, X. & Ivashkiv, L. B. TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J. J Exp Med. 209, 319-334 (2012).
13. Mundy, G. R. Osteoporosis and inflammation. Nutr Rev. 65, S147-151 (2007).
14. Tanaka, Y., Nakayamada, S. & Okada, Y. Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy 4, 325-328 (2005).
15. Reginster, J. Y. & Burlet, N. Osteoporosis: a still increasing prevalence. Bone 38, S4-9 (2006).
16. Abu-Taha, M. et al. Menopause and ovariectomy cause a low grade of systemic inflammation that may be prevented by chronic treatment with low doses of estrogen or losartan. J Immunol 183, 1393-1402 (2009).
17. Saeed, H. et al. Telomerase-deficient mice exhibit bone loss owing to defects in osteoblasts and increased osteoclastogenesis by inflammatory microenvironment. J Bone Miner Res. 26, 1494-1505 (2011).
18. Yu, X., Huang, Y., Collin-Osdoby, P. & Osdoby, P. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J Bone Miner Res. 19, 2065-2077 (2004).
19. Sweeney, S. E., Mo, L. & Firestein, G. S. Antiviral gene expression in rheumatoid arthritis: role of IKKepsilon and interferon regulatory factor 3. Arthritis Rheum. 56, 743-752 (2007).
20. Corr, M., Boyle, D. L., Ronacher, L., Flores, N. & Firestein, G. S. Synergistic benefit in inflammatory arthritis by targeting I kappaB kinase epsilon and interferon beta. Ann Rheum Dis. 68, 257-263 (2009).
21. Vervoordeldonk, M. J., Aalbers, C. J. & Tak, P. P. Interferon beta for rheumatoid arthritis: new clothes for an old kid on the block. Ann Rheum Dis. 68, 157-158 (2009).
22. Dieguez-Gonzalez, R. et al. Genetic variation in the nuclear factor kappaB pathway in relation to susceptibility to rheumatoid arthritis. Ann Rheum Dis. 68, 579-583 (2009).
23. Hammaker, D., Boyle, D. L. & Firestein, G. S. Synoviocyte innate immune responses: TANK-binding kinase-1 as a potential therapeutic target in rheumatoid arthritis. Rheumatology 51, 610-618 (2012).
24. Sun, Q. et al. TBK1 mediates critical effects of measles virus nucleocapsid protein (MVNP) on pagetic osteoclast formation. J Bone Miner Res. 29, 90-102 (2014).
25. Bell, J. Amlexanox for the treatment of recurrent aphthous ulcers. Clin Drug Investig. 25, 555-566 (2005).
26. Makino, H., Saijo, T., Ashida, Y., Kuriki, H. & Maki, Y. Mechanism of action of an antiallergic agent, amlexanox (AA-673), in inhibiting histamine release from mast cells. Acceleration of cAMP generation and inhibition of phosphodiesterase. Int Arch Allergy Appl Immunol. 82, 66-71 (1987).
27. Reilly, S. M. et al. An inhibitor of the protein kinases TBK1 and IKK-varepsilon improves obesity-related metabolic dysfunctions in mice. Nat Med. 19, 313-321 (2013).
28. Asagiri, M. & Takayanagi, H. The molecular understanding of osteoclast differentiation. Bone 40, 251-264 (2007).
29. Bruzzaniti, A. & Baron, R. Molecular regulation of osteoclast activity. Rev Endocr Metab Disord. 7, 123-139 (2006).
30. Ruocco, M. G. & Karin, M. Control of osteoclast activity and bone loss by IKK subunits: new targets for therapy. Adv Exp Med Biol. 602, 125-134 (2007).
31. Ruocco, M. G. et al. I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med. 201, 1677-1687 (2005).
32. Takayanagi, H. et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev cell 3, 889-901 (2002).
33. Grigoriadis, A. E. et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266, 443-448 (1994).
34. Matsuo, K. et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem. 279, 26475-26480 (2004).
35. Chang, J. et al. Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med. 15, 682-689 (2009).
36. Alles, N. et al. Suppression of NF-kappaB increases bone formation and ameliorates osteopenia in ovariectomized mice. Endocrinology 151, 4626-4634 (2010).
37. Greenblatt, M. B., Shim, J. H. & Glimcher, L. H. Mitogen-activated protein kinase pathways in osteoblasts. Annu Rev Cell Dev Biol. 29, 63-79 (2013).
38. Sun, L. et al. Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss. Proc Natl Acad Sci U S A. 105, 4289-4294 (2008).
39. Delhase, M. et al. TANK-binding kinase 1 (TBK1) controls cell survival through PAI-2/serpinB2 and transglutaminase 2. Proc Natl Acad Sci U S A. 109, E177-186 (2012).
40. Guan, H., Zhao, L., Cao, H., Chen, A. & Xiao, J. Epoxyeicosanoids suppress osteoclastogenesis and prevent ovariectomy-induced bone loss. FASEB J. 29, 1092-101 (2015).
41. Koga, T. et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428, 758-763 (2004).
42. Takahashi, N., Udagawa, N., Kobayashi, Y. & Suda, T. Generation of osteoclasts in vitro, and assay of osteoclast activity. Methods Mol Med. 135, 285-301 (2007).
43. Li, C. et al. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKLmediated NF-κ B and MAPK signaling pathways. J Bone Miner Res. 26, 644-656 (2011).
44. Sreejit, P., Dilip, K. B. & Verma, R. S. Generation of mesenchymal stem cell lines from murine bone marrow. Cell Tissue Res. 350, 55-68 (2012).
45. Tondreau, T. et al. Isolation of BM mesenchymal stem cells by plastic adhesion or negative selection: phenotype, proliferation kinetics and differentiation potential. Cytotherapy 6, 372-379 (2004).
46. Beyer Nardi, N. & da Silva Meirelles, L. Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handb Exp Pharmacol. 174, 249-282 (2006).
47. Koide, M. et al. Diphenylhydantoin inhibits osteoclast differentiation and function through suppression of NFATc1 signaling. J Bone Miner Res. 24, 1469-1480 (2009).
48. Takatsuna, H. et al. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. J Bone Miner Res. 20, 653-662 (2005).
49. Bouxsein, M. L. et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 25, 1468-1486 (2010).
50. Lee, S. K. et al. Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss. J Bone Miner Res. 21, 695-702 (2006).
51. Montero, A. et al. Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest. 105, 1085-1093 (2000).
52. Guan, H. et al. Decitabine represses translocated MYC oncogene in Burkitt lymphoma. J Pathol. 229, 775-783 (2013).
53. Guan, H. et al. KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma. Blood 116, 1469-1478 (2010).